Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Vaxart, Inc.

Make norovirus vaccine Phase 1b booster trial data available

Delivered after the deadline (29 days after the deadline)

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
25 Feb 2021
Due
30 Jun 2021
Delivered
29 Jul 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“Data are expected to be available in the first half of 2021.”
  • SourceVaxart, Inc. Form 8-K press release, 2021-02-25
  • FilingSEC filing index
  • Deadline as statedin the first half of 2021
  • Deadline used30 Jun 2021, the last day of the stated period
  • TypeProject
  • Permanent referenceKI-C-2021-VXRT-024552
    Cite as https://keptindex.org/c/KI-C-2021-VXRT-024552/ — this address never changes.

What we found

Evidence strength A What the grades mean

Filings say booster trial results were announced on July 29, 2021, after the end-of-June 2021 deadline for first-half data.

  • A
    Vaxart, Inc. 10-K filed 2022-02-24 Regulatory filing · published 24 Feb 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In results announced on July 29, 2021, we reported that we were able to successfully boost immune responses with the G1.1 norovirus tablets in prior vaccinated subjects.” ✓ confirmed on the page
  • A
    Vaxart, Inc. 10-K filed 2022-02-24 Regulatory filing · published 24 Feb 2022 · retrieved 26 Oct 2026 · kept permanently by the SEC
    “In results announced on July 29, 2021, we reported that we were able to successfully boost immune responses with the G1.1 norovirus tablets in prior vaccinated subjects.” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical readout
Indicative materiality
Medium rules
Action
Make
Deliverable
Norovirus vaccine program booster dose trial data
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
Medium

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Vaxart, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-VXRT-024552 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.